Syndax Pharmaceuticals (SNDX) Share-based Compensation (2015 - 2026)

Syndax Pharmaceuticals' Share-based Compensation history runs 12 years deep, the most recent figure standing at $12.1 million for Q1 2026.

• On a quarterly basis, Share-based Compensation rose 16.12% year-over-year to $12.1 million in Q1 2026; TTM through Mar 2026 was $49.2 million, a 10.49% increase from a year earlier, with the FY2025 full-year figure at $78.7 million, down 3.55% from the prior year.
• Share-based Compensation climbed to $12.1 million in Q1 2026 per SNDX's latest filing, from $11.3 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $13.8 million in Q2 2025 and bottomed at $346000.0 in Q3 2022.
• The 5-year median for Share-based Compensation is $8.9 million (2024), against an average of $8.6 million.
• Across the five-year window, Share-based Compensation plunged 89.77% in 2022 and soared 2304.91% in 2023, its largest moves.
• Year by year, Share-based Compensation stood at $4.2 million in 2022, then jumped by 96.35% to $8.3 million in 2023, then jumped by 47.68% to $12.3 million in 2024, then dropped by 8.48% to $11.3 million in 2025, then rose by 7.1% to $12.1 million in 2026.
• Per Business Quant, the three latest SNDX Share-based Compensation figures stand at $12.1 million (Q1 2026), $11.3 million (Q4 2025), and $12.1 million (Q3 2025).